What is the purpose of this transaction?

It aligns with the group’s strategic transformation, positioning in biotech.

What is the transaction amount?

Over NT$302 million, specifically NT$302,811,565 in total.

What is the ownership percentage?

Cumulative holding of 2,606,000 shares, representing 3.76% ownership.

Is this a related-party transaction?

No, there is no special relationship; it is not a related-party transaction.

What is the financial impact?

Represents 0.77% of total assets and 1.18% of equity. Working capital is negative NT$36 billion.

AI News NQ Analysis

Kesheng's Subsidiary Yikuang Announces Cumulative Acquisition of Bangte Biotech Shares Exceeding NT$300 Million Within One Year

NQ Score 44/100

N1 Content Completeness 5

AI Summary (NQ-processed)

Yikuang Co., Ltd., a subsidiary of Kesheng, announced the cumulative acquisition of ordinary shares in Bangte Biotechnology Co., Ltd. exceeding NT$300 million within one year. This strategic investment aligns with the group's transformation goals.

AI Analysis

Frequently Asked Questions

Q: What is the purpose of this transaction?: A: It aligns with the group’s strategic transformation, positioning in biotech.
Q: What is the transaction amount?: A: Over NT$302 million, specifically NT$302,811,565 in total.
Q: What is the ownership percentage?: A: Cumulative holding of 2,606,000 shares, representing 3.76% ownership.
Q: Is this a related-party transaction?: A: No, there is no special relationship; it is not a related-party transaction.
Q: What is the financial impact?: A: Represents 0.77% of total assets and 1.18% of equity. Working capital is negative NT$36 billion.